Magnet Biomedicine Selects Simplicis's Ledger(TM) Platform to Lead Innovation in Compound Management
Wednesday, March 12, 2025
BOSTON, March 4, 2025 /PRNewswire/ -- Magnet Biomedicine, a biotechnology company advancing molecular glue discovery through rational selection and design, has selected Simplicis's Ledger(TM) platform after a rigorous evaluation process that considered several leading competitors. Simplicis's unmatched combination of innovation, adaptability, and cost-efficiency proved to be the ideal choice to support Magnet's cutting-edge research operations.
Magnet Biomedicine is recognized for its TrueGlue(TM) discovery platform, which leverages advancements in human biology and proteomics to develop next-generation molecular glues targeting critical unmet medical needs. Choosing Simplicis's Ledger(TM) platform enables Magnet to advance its mission to deliver transformative therapeutic solutions.
Strategic Decision to Partner with Simplicis
Liam Hudson, Associate Director at Magnet Biomedicine, explained the decision-making process:
"After evaluating multiple platforms, it was clear that Simplicis offered a combination of Functionality, technical knowledge and value that others could not match. Ledger(TM) stood out as the solution that best aligns with our operational needs and future growth.
Hudson also emphasized the importance of collaboration and innovation:
"Simplicis's pragmatic and forward-thinking approach equips us with the tools to enhance our compound management capabilities and scale efficiently."
Driving Operational Efficiency with Advanced Technology
Gina Chen, Compound Management Lead at Magnet Biomedicine, highlighted the user-centric design and adaptability of Simplicis's Ledger(TM) platform:
"Ledger(TM) delivers all the features we needed--and more--in a streamlined, user-friendly interface. Its ability to support pre-validation of requests ensures accountability and simplifies workflows across teams."
Chen also noted the impact of advanced automation on team productivity:
"With Simplicis, we've seen a significant reduction in manual tasks, allowing us to focus on the science rather than the logistics."
Integration and Flexibility as Key Differentiators
James Ralff, Research Associate at Magnet Biomedicine, praised Ledger(TM) seamless integration capabilities:
"Ledger(TM) integrates effortlessly with our existing workflows, offering intuitive tools that simplify data management and enable us to work more efficiently."
Ralff highlighted the platform's ability to handle complex workflows:
"Simplicis's capabilities empower us to mine data effectively, streamline plate mapping, and optimize our processes in ways that were previously unattainable."
Implementation and Looking Ahead
Magnet Biomedicine has already begun its transition to the Ledger(TM) platform, with a full go-live expected in February 2025. The implementation process includes migrating legacy systems, integrating key hardware, and training staff to leverage the platform's full potential. The partnership is expected to drive significant operational efficiencies, enhance collaboration, and provide a strong foundation for future growth.
About Magnet Biomedicine
Magnet Biomedicine is a biotechnology company advancing molecular glue discovery through rational selection and design. The company's TrueGlue(TM) discovery platform integrates cutting-edge science and technology to develop therapeutic solutions that address critical unmet medical needs, offering transformative potential for precision medicine.
For more information, visit magnetbio.com.
About Simplicis
Simplicis is a leading provider of laboratory information management systems (LIMS) designed to optimize workflows, enhance data management, and drive innovation. The Ledger(TM) platform is a state-of-the-art solution tailored to meet the evolving needs of the biotechnology and pharmaceutical sectors, delivering efficiency and scalability for research organizations worldwide.
For more information, visit simplicis.com
Media Contact:
Jennifer Franklin
Vice President of Administration & Operations
Magnet Biomedicine
info@magnetbio.com
(617) 741-0974
View original content to download multimedia:https://www.prnewswire.com/news-releases/magnet-biomedicine-selects-simpliciss-ledger-platform-to-lead-innovation-in-compound-management-302391921.html
SOURCE Simplicis
|
|
|
|
|
 |
Energy Toolbase Launches Energy Storage Partnership with Sungrow to Support PowerStack 255CS and PowerTitan 2.0 | Jan 22, 2026
|
|
RS now offers Phoenix Contact's pioneering new NearFi technology | Jan 22, 2026
|
|
MetaOptics to Showcase Five Breakthrough Metalens-Powered Products at CES 2026 | Jan 22, 2026
|
|
Fresco Raises EUR15m Series C to Power the Future of AI-Driven Cooking and the Connected Kitchen Ecosystem | Jan 22, 2026
|
|
No Assembly Required: Barrett Distribution Centers Powers Maxwood Furniture's West Coast DTC Expansion | Jan 22, 2026
|
|
SCAILIUM Debuts "AI Production Layer" to Overcome GPU Starvation and Slash AI Energy Waste | Jan 22, 2026
|
|
Hesai Recognized as the Only Lidar Company on Morgan Stanley's "Humanoid Tech 25" of Global Robotics Leaders | Jan 22, 2026
|
|
Einride and IonQ Partnership Uses Quantum Computing to Optimize the Logistics of Electric and Autonomous Freight | Jan 22, 2026
|
|
Daikin Applied Invests $163M in Advanced R&D Test Lab to Bolster HVAC Innovation for Data Centers and Beyond | Jan 22, 2026
|
|
Lumana Surpasses 50,000 Cameras, Cementing Its Leadership in AI Video Surveillance | Jan 22, 2026
|
|
|
